Straits Times Index
3,332.80 -10.55 (-0.32%) Nikkei
39,583.08 +241.54 (+0.61%) Hang Seng
17,718.61 +2.14 (+0.01%) FTSE 100
8,164.12 -15.56 (-0.19%) Bitcoin USD
60,802.18 -1,239.79 (-2.00%) CMC Crypto 200
1,265.69 -18.14 (-1.41%)
AGEN Jul 2024 13.000 call
| Previous close | 2.2000 |
| Open | 2.2000 |
| Bid | 3.6000 |
| Ask | 4.4000 |
| Strike | 13.00 |
| Expiry date | 2024-07-19 |
| Day's range | 2.2000 - 2.2000 |
| Contract range | N/A |
| Volume | |
| Open interest | 62 |
- Business Wire
Significant Tumor Reductions in Neoadjuvant MSS Colon Cancer Patients Treated with Botensilimab/Balstilimab Presented at ESMO GI Conference
LEXINGTON, Mass., June 28, 2024--Agenus Inc. ("Agenus") (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced results from an investigator-sponsored trial (IST) of botensilimab and balstilimab (BOT/BAL) in the neoadjuvant setting for colon cancer. Data were presented at the 2024 European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Congress in Munich, Germany.
- Business Wire
Cancer Therapy Evaluation Program Announces Availability of Botensilimab for Clinical Studies
LEXINGTON, Mass., June 27, 2024--Agenus Inc. ("Agenus") (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced that the Cancer Therapy Evaluation Program (CTEP) is accepting Letters of Intent (LOIs) to conduct clinical studies using botensilimab (BOT), a human Fc enhanced next-generation anti-cytotoxic T-lymphocyte associated protein 4 (CTLA-4) antibody, which is being developed by CTEP as an anticancer agent in collaboration with Agenus Inc.
- Business Wire
Agenus Announces Appointment of Dr. Jennifer Buell to Its Board of Directors
LEXINGTON, Mass., June 17, 2024--Agenus Inc. ("Agenus") (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, is pleased to announce the appointment of Dr. Jennifer Buell to its Board of Directors, on June 11, 2024, effective immediately. Dr. Buell will maintain her active and ongoing role as the President and CEO of MiNK Therapeutics, in addition to her responsibilities as Chairman of the Executive Council at Agenus. Her continued leadership at MiNK ensures
